Megan Rosengarten
Known title: DirectorCIK: 0001876577
Associated companies
Transaction History
| STIM | ▲ Buy | Grant | 30,000 | $0 | 5/28/2026 | View on chart |
| STIM | ▲ Buy | Grant | 30,000 | — | 5/22/2025 | View on chart |
| STIM | ▲ Buy | Grant | 25,000 | — | 5/30/2024 | View on chart |
| STIM | ▲ Buy | Grant | 36,364 | — | 5/25/2023 | View on chart |
| STIM | ▲ Buy | Grant | 38,910 | — | 5/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
STIM shifts focus from devices to psychedelic infrastructure
Neuronetics announced it is moving away from solely manufacturing its TMS device and is building a platform to support psychedelic therapies. The change aims to broaden the company's role in the emerging mental-health market. The stock is currently trading near its $1.19 support level and has an RSI of 25.4, indicating a low momentum environment.
STIM shifts focus from devices to psychedelic infrastructure. Neuronetics announced it is moving away from solely manufacturing its TMS device and is building a platform to support psychedelic therapies. The change aims to broaden the company's role in the emerging mental-health market. The stock is currently trading near its $1.19 support level and has an RSI of 25.4, indicating a low momentum environment.